Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.72 +0.30 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
43 44 Next >
AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents
The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above)... 
Via Benzinga
EMA Reviewing Cases Of Multisystem Inflammatory Syndrome After Pfizer COVID Shot
Europe Medicines Agency (EMA) said it is reviewing cases of the multisystem inflammatory syndrome (MIS) after inoculation with COVID-19 vaccines, following a similar... 
Via Benzinga
Exposures COVID-19
AstraZeneca, EU Reach Settlement On COVID-19 Vaccine Delivery
AstraZeneca Plc (NASDAQ: AZN) and the European Commission have settled on the delivery of pending COVID-19 vaccine doses by the Company. The agreement ends legal... 
Via Benzinga
Exposures COVID-19
White House Commits $3B To Boost COVID-19 Vaccine Supply Chain: Report
The U.S. will invest $3 billion in the COVID-19 vaccine supply chain within the coming weeks, White House coronavirus response coordinator Jeff Zients said Thursday.... 
Via Benzinga
Exposures COVID-19
Can Vaccine Help In Long Term COVID-19 Symptoms? UK Study Gives Encouraging Answer
According to findings from a new U.K. study, along with reducing the risk of severe disease and hospitalization, COVID-19 vaccines can also lower the odds of having long-term... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
The Rising Delta Variant
China is not only cracking down on kiddie playtime. It also is absorbing bankruptcy claims from real estate developer Evergrande. 
Via Talk Markets
Topics Bankruptcy
Exposures Financial Legal
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season
From AstraZeneca
Via Business Wire
What's The Risk Of Blood Cots After Getting A COVID-19 Vaccination? This Study Shows Encouraging Data
U.K. researchers have published a new paper showing that the risk of blood clots is much higher after a COVID-19 infection than the COVID-19 vaccination. The data... 
Via Benzinga
Exposures COVID-19
EU Says Without EMA Approval COVID-19 Boosters May Face Higher Legal Risks: Reuters
European Union countries that decide to use COVID-19 vaccine booster shots may face increased legal risks, the European Commission said. Related Content: Pfizer, BioNTech... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Drug Shows Promise In Copper Build-Up Genetic Disease
AstraZeneca plc (NASDAQ: AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the primary goal of... 
Via Benzinga
5 Best Dividend Stocks To Buy Now
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Thailand-Developed System Can Draw Out More COVID-19 Vaccine Doses: All You Need To Know
Researchers in Thailand have developed a machine to draw out COVID-19 vaccine doses more efficiently and optimize lower-than-expected supplies. According to researchers at... 
Via Benzinga
Exposures COVID-19
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Exposures COVID-19 Interest Rates Product Safety
Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the... 
Via Talk Markets
Exposures Product Safety
Global Stocks & Commodities Update
A quick look at oil, cobalt, and some of the stocks in my portfolio. 
Via Talk Markets
3 Top COVID Vaccine Stocks That Wall Street Is Bullish About
Hint: Pfizer, BioNTech, and Moderna didn't make the list. 
Via The Motley Fool
Exposures COVID-19
Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to... 
Via Benzinga
AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%
A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo.... 
Via Benzinga
Exposures COVID-19
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by... 
Via Benzinga
Exposures Product Safety
Here's What Recent News From the FDA Means for AstraZeneca
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. 
Via The Motley Fool
Exposures Product Safety
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
From AstraZeneca
Via Business Wire
Are COVID-19 Vaccines Effective Against Delta Variant? Probably Not So Much
COVID-19 vaccines from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) and Oxford–AstraZeneca Plc (NASDAQ: AZN) have shown effectiveness... 
Via Benzinga
Exposures COVID-19
Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial
AstraZeneca Plc's (NASDAQ: AZN) bispecific antibody derived from Compugen Ltd's (NASDAQ: CGEN) COM902 will advance into clinical development. ... 
Via Benzinga
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
Cannabis Movers & Shakers: Jay-Z-Backed The Parent Co. Appoints First Black CEO In Major Public Cannabis Company, CannaSafe, HEXO And Delta 9 Each Announce New Appointments
CannaSafe's CEO Departure, New Management Team Appointed Amid Reorganization Cannabis testing laboratory CannaSafe... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Here's What This Label Expansion Means for AstraZeneca Investors
The recent decision by the EMA to approve Forxiga for the treatment of chronic kidney disease is a huge boost for the pharmaceutical company. 
Via The Motley Fool
3 Top Biotech Stocks to Buy in August
Each of these companies makes for a great vehicle to play an aging demographic. 
Via The Motley Fool
Sunday Update - UK Disarray, Brazilian Kisses
News from the UK, China and Brazil, with the latest from Cosan. 
Via Talk Markets
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.